Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arterial Bevacizumab and Intrathecal Tislelizumab for Recurrent GBM
NCT05811793Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Apr 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and bevacizumab in glioblastoma (GBM), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Progression-Free Survival at 10 months. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
tislelizumabbevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05811793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05811793.